Potential Noninvasive Biomarker of EoE Disease Activity Identified
By LabMedica International staff writers Posted on 24 May 2016 |

Image: A micrograph of eosinophilic esophagitis (EoE), H&E stain. Characteristic features are present: Abundant eosinophils – criteria vary; one common definition is: > 20 eosinophils/0.24 mm2; Papillae are elongated; papillae reach into the top 1/3 of the epithelial layer; Basal cell hyperplasia; > 3 cells thick or >15% of epithelial thickness; Spongiosis (Photo courtesy of Michael Bonert / Wikimedia).
Researchers have identified a potential blood-based marker of disease activity for the severe and often painful food allergic disease eosinophilic esophagitis (EoE) – possibly leading to a blood test, which could spare EoE patients, often children, the discomfort and risk of the currently used invasive endoscopic monitoring procedures.
Researchers at the Cincinnati Center for Eosinophilic Disorders (CCED) of Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) led the study. “Adults and children with EoE can be on highly restricted diets of formula alone or only a few foods,” said Patricia C. Fulkerson, MD, PhD, senior study author, “One of the major obstacles to families participating in studies to introduce foods back into the child’s diet is the need for endoscopy after each food is tried to see whether or not it triggers disease activity.”
The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires endoscopy to collect esophageal tissue biopsies. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, require additional endoscopic exams to assess for disease flare-ups.
Prior research has demonstrated that testing blood of EoE patients is not a clinically useful indication of active disease because eosinophil levels in blood do not correlate well with levels in the esophagus. This led the team to investigate a precursor cell to eosinophils, a lineage-committed eosinophil progenitor (EoP), as a potential marker. They found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker.
The authors emphasize that additional research is needed to validate the marker before routine clinical use. “This clinical study is the first to investigate EoP levels in patients with EoE and identifies a potential new noninvasive biomarker,” said study author Vincent A. Mukkada, MD, physician at Cincinnati Children’s and CCED member, “This work is an essential step toward improving outcomes for patients with EoE. It will be followed by repeated testing of more patients and with sequential measurements of EoP levels in the same patient during different disease states.”
Allergic diseases have been on the rise over the past 20 years. The CCED team has previously reported that incidence of EoE is estimated at 1 of 1,000 people. Their research has also shown that EoE is caused by a combination of genetic and environmental factors, and is primarily mediated by an immunologic response to foods. The hallmark of EoE is swelling and inflammation in the esophagus, accompanied by high levels of eosinophils.
The study, by Morris DW et al, was published May 16, 2016, in the Journal of Allergy and Clinical Immunology.
Related Links:
Cincinnati Children’s Hospital Medical Center
Researchers at the Cincinnati Center for Eosinophilic Disorders (CCED) of Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) led the study. “Adults and children with EoE can be on highly restricted diets of formula alone or only a few foods,” said Patricia C. Fulkerson, MD, PhD, senior study author, “One of the major obstacles to families participating in studies to introduce foods back into the child’s diet is the need for endoscopy after each food is tried to see whether or not it triggers disease activity.”
The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires endoscopy to collect esophageal tissue biopsies. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, require additional endoscopic exams to assess for disease flare-ups.
Prior research has demonstrated that testing blood of EoE patients is not a clinically useful indication of active disease because eosinophil levels in blood do not correlate well with levels in the esophagus. This led the team to investigate a precursor cell to eosinophils, a lineage-committed eosinophil progenitor (EoP), as a potential marker. They found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker.
The authors emphasize that additional research is needed to validate the marker before routine clinical use. “This clinical study is the first to investigate EoP levels in patients with EoE and identifies a potential new noninvasive biomarker,” said study author Vincent A. Mukkada, MD, physician at Cincinnati Children’s and CCED member, “This work is an essential step toward improving outcomes for patients with EoE. It will be followed by repeated testing of more patients and with sequential measurements of EoP levels in the same patient during different disease states.”
Allergic diseases have been on the rise over the past 20 years. The CCED team has previously reported that incidence of EoE is estimated at 1 of 1,000 people. Their research has also shown that EoE is caused by a combination of genetic and environmental factors, and is primarily mediated by an immunologic response to foods. The hallmark of EoE is swelling and inflammation in the esophagus, accompanied by high levels of eosinophils.
The study, by Morris DW et al, was published May 16, 2016, in the Journal of Allergy and Clinical Immunology.
Related Links:
Cincinnati Children’s Hospital Medical Center
Latest Pathology News
- AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
- AI-Powered Imaging Enables Faster Lung Disease Treatment
- New Laboratory Method Speeds Diagnosis of Rare Genetic Disease
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more
Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
Genetic diseases are the leading identifiable cause of infant mortality, and early diagnosis is crucial to improve patient outcomes. In the neonatal and pediatric intensive care units (NICU and PICU),... Read more
AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
Cancer remains a major challenge in healthcare due to difficulties in early detection and accurate diagnosis. Many cancers are diagnosed at advanced stages, limiting treatment options and impacting survival rates.... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
2025 COMPAMED Innovation Forum Highlights Pioneering Work in Cancer Diagnostics
Cancer cases are among the biggest challenges faced by global healthcare systems. The incidence has risen in recent decades, not least on account of demographic change and escalating risk factors.... Read more
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more